Kimia Biosciences Limited

Healthcare — Drug Manufacturers - Specialty & Generic · BSE

₹32.10−₹1.46 (−4.35%)

DalalBaazaar Score

36 / 100

🔴 Weak

Verdict

CAUTION

Risk

High

Driven by high debt relative to equity, micro-cap size, which brings thin liquidity, falling profits.

In simple words: Profitability data is thin for this company, but sales are shrinking. Debt is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:47 pm

Understanding the Business

Company site ↗

The 60-second version of Kimia Biosciences Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Kimia Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India and internationally.

IndustryDrug Manufacturers - Specialty & Generic

SectorHealthcare

Employees205

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, DR. REDDY S LABORATORIES, CIPLA LTD, DIVI S LABORATORIES LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

DalalBaazaar Score

36/ 100

Weak

Weighted across six categories. Every point is explained below.

✗ Debt/Equity of 1.96x is high — earnings must service borrowings before shareholders see anything

Quality vs. Valuation

Company Quality

38/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

25/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

vs. its own history

Not enough price and earnings history

vs. sector peers

Not enough peers with a usable P/E

vs. generic bands

No P/E available

EV/EBITDA

—

PEG

—

Red Flags

1 item require attention · 1 high

🔴High leverageFinancial
Debt/Equity of 1.96x — earnings must service borrowings before shareholders see anything.

Investment Thesis

🟢 Bull CaseWhat could make this work?

No clear supporting case emerges from the available numbers.

🔴 Bear CaseWhat could go wrong?

Leverage amplifies any setback
Debt/Equity of 1.96x. Interest is payable whether or not the business has a good year.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Free cash flow remains positive✗ not reported
Profit that never becomes cash eventually stops being profit.

Investment Checklist

2 / 6 checks passed

✗ Healthy net margin (≥ 10%)
✗ Manageable leverage (Debt/Equity < 1.0)
✗ Revenue growing year-over-year
✗ Profit growing year-over-year
✓ Not buying right at the 52-week high
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

0 good · 7 neutral · 4 weak

Market Cap

₹152 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

Not available

No data

Source didn't return this field

P/B Ratio

7.09x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

Not available

No data

Source didn't return this field

ROE

Not available

No data

Source didn't return this field

ROCE

Not available

No data

Source didn't return this field

Debt/Equity

1.96x

High

High leverage

Revenue Growth (YoY)

-12.1%

Shrinking

Sales are contracting

Profit Growth (YoY)

-38.5%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

Not available

No data

Source didn't return this field

More Metrics

Operating Margin

6.0%

Average

Average margins

Net Margin

6.4%

Average

Average bottom-line conversion

Beta (vs Nifty)

1.16

Market-like

Moves roughly in line with the market

52W Range Position

44%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

32.1 / 30.0

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

56.7

Neutral momentum

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

91.0%

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
DR. REDDY S LABORATORIES	31.0x	8.8%
CIPLA LTD	31.8x	9.8%
DIVI S LABORATORIES LTD	83.0x	17.5%

Recent News

1 mixed2 negative3 general

Kimia Biosciences Ltd. Share Price: Price Action Analysis

Univest, 13 Aug

Kimia Biosciences closes trading window from October 1 ahead of Q2FY27 results

scanx.trade, 26 SeptResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Kimia Biosciences standalone net profit declines 40.00% in the June 2026 quarter

Business Standard, 10 AugResults

🔴Potentially negativeReported deterioration, which feeds the growth and margin inputs on this page directly.

Kimia Biosciences fixes Sept 21 record date for 33rd AGM

scanx.trade, 28 Sept

KIMIA BIOSCIENCES LIMITED Share Price

Upstox, 22 Mar

Kimia Biosciences FY26 net profit falls 22.7% to ₹743.37 lakh

scanx.trade, 29 MayResults

🔴Potentially negativeReported deterioration, which feeds the growth and margin inputs on this page directly.

Watch Items

Revenue growth is negative (-12.1%) on the latest reported period — check if this is one-off or a trend.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
5 metrics couldn't be retrieved for this stock — this is more common for smaller or thinly-covered listings.

DalalBaazaar Thesis

MiddlingGrowth · Profitability

WeakBusiness Quality · Financial Health · Valuation · Risk

Points for each in the Score ↑

Weak on the fundamentals

Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 1 high-severity red flag sits above this conclusion and should be read first.

1 of 1 tripwires tripped — Free cash flow remains positive · see Key things to watch ↑